Please assess the completion status of the following clinical trial:

Trial Title: BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Juvenile Rheumatoid Arthritis or Juvenile Idiopathic Arthritis;~* Current active arthritis;~* Failed treatment with at least one disease modifying anti-rheumatic drug (DMARD);~* Subjects must discontinue use of any DMARD other than methotrexate prior to the first dose of study medication~Exclusion Criteria:~* Presence of infection or history of frequent acute or chronic infections;~* Joint replacement surgery required during the study or history of surgery on more than 5 joints;~* Live vaccines within 3 months of the first dose of study medication;~* Unresolved serious bacterial infection or chronic bacterial infection;~* Subjects who currently have intermittent fever due to JRA/JIA, rheumatoid rash, hepato-splenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Abatacept (Type: ACTIVE_COMPARATOR): Double Blind Period
- Placebo (Type: PLACEBO_COMPARATOR): Double Blind Period
- Abatacept - Open Label (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).